Wegovy Price Cuts 2026: Every Discount, Deal, and Savings Program

The price of Wegovy has fallen more in the past six months than in the entire three years since its launch. Novo Nordisk is responding to competition from every direction—Eli Lilly’s Zepbound vials at $299, Canadian generics approaching, oral Wegovy cannibalizing injectable sales, and IRA-negotiated Medicare prices looming in 2027. The result? Patients have more affordable access options than ever before.

Current Wegovy Pricing: March 2026

What Changed: The Competitive Pressure Timeline

Novo Nordisk didn’t cut prices out of generosity—they’re responding to the most competitive pressure the GLP-1 market has ever seen. In December 2025, Eli Lilly reduced Zepbound vial prices, bringing the starting dose down to $299 per month through LillyDirect. That same month, the FDA approved oral Wegovy, which Novo Nordisk priced aggressively at $149 starting to capture the needle-averse market before Eli Lilly’s orforglipron arrives.

The GoodRx-Novo Nordisk partnership, announced in November 2025, created $199 introductory pricing for first-time Ozempic and Wegovy users. And the looming arrival of Canadian generic semaglutide—potentially at $78 CAD per month—made it clear that maintaining $1,300 list prices was unsustainable.

How Wegovy Compares to Zepbound in 2026

For cash-pay patients, the pricing competition between Wegovy and Zepbound has never been tighter. LillyDirect offers Zepbound vials at $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for maintenance doses of 7.5–15 mg. Wegovy injectable is $349 per month for all doses through NovoCare, which means Zepbound is actually cheaper at the starting dose, while Wegovy is cheaper at higher maintenance doses.

The oral Wegovy pill adds another dimension. At $299 per month for the full 25 mg dose, it matches Zepbound vial pricing for starters. The tradeoff is efficacy: the OASIS trials showed approximately 13.6% weight loss with oral Wegovy at 64 weeks, compared to the 15–17% typically seen with injectable Wegovy and the 20%+ seen with Zepbound at higher doses. For many patients, the convenience of a daily pill outweighs the modest efficacy difference.

The Manufacturer Savings Card: Still the Best Deal

If you have commercial insurance that covers Wegovy, the Novo Nordisk savings card remains the single best way to reduce your out-of-pocket cost. With a qualifying plan, the savings card can bring your monthly copay down to as low as $25. The card is available through novocare.com and can be applied at any participating pharmacy.

Important exclusions apply: the savings card does not work with Medicare, Medicaid, TRICARE, or any other government-funded insurance program. Patients covered by these programs should explore the GENEROUS model (Medicare) or state Medicaid formularies (which vary significantly by state).

What’s Coming Next: IRA Negotiated Prices in 2027

The Inflation Reduction Act selected both Ozempic and Wegovy for Medicare price negotiations. The negotiated prices were announced November 30, 2025, and take effect January 1, 2027. While the exact negotiated prices haven’t been fully disclosed, the combination of the GENEROUS model and IRA negotiations means Medicare patients will pay significantly less than they do today.

The bottom line: if you’ve been putting off GLP-1 treatment because of cost, 2026 is the year the math finally works. Between oral Wegovy at $149 to start, Zepbound vials at $299, self-pay injectable Wegovy at $349, and savings cards that can bring insured copays to $25, there are more affordable access points than at any time since these medications launched.